News & Media | Lee's Pharmaceutical
20 DEC 2018

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

PALO ALTO, CA, AND HONG KONG – December 19, 2018 – Auransa, Inc., an artificialintelligence (AI)-driven pharmaceutical company developing precision medicines in areas ofsignificant unmet medical need……





News & Media

09/12/2022
Dr. LI Xiao Yi Benjamin, the Founder of Lee’s Pharm was interviewed by Mediazone Group during “Most Valuable Companies in Hong Kong 2022 Awards” Ceremony
Hong Kong, November 30, 2022, the Most Valuable Companies in Hong Kong (HKMVC) 2022 Awards Ceremony organized by Mediazone Group, a reputable international business magazine publisher was successfully held at the Royal Pacific Hotel, Tsim Sha Tsui. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was honoured with the HKMVC 2022 award with the title of “Most Innovative Pharmaceutical Company”, in recognition of its extensive research and development experience and solid infrastructures. Dr. LI Xiaoyi Benjamin, the Founder and Director of Lee’s Pharm was invited to attend the ceremony and receive the award.

Interview session was featured in the ceremony, giving insight into the achievements and latest development of winning companies. According to Dr. Li, Lee’s Pharm has launched various products in this year, such as the in-licensed products, Teglutik® and INOmax®, which help patients suffering from rare disease. To date, the Group has more than 40 products in its pipeline from early- to late-stage development. More products are expected to be launched in 2023, such as an oncology product treating cervical cancer. Lee’s Pharm focuses on China, Hong Kong and Taiwan market, and is expanding its business to Southeast Asia in 2023 by providing innovative pharmaceutical products, especially in the field of rare disease.

Please click on the video below to watch the full interview.
Hong Kong, November 30, 2022, the Most Valuable Companies in Hong Kong (HKMVC) 2022 Awards Ceremony organized by Mediazone Group, a reputable international business magazine publisher was successfully held at the Royal Pacific Hotel, Tsim Sha Tsui. Lee’s Pharmaceutical Holdings...
20/10/2020
Zhaoke Ophthalmology and Nevakar Entered Into A License Agreement for NVK-002 — Introducing The Eye Treatment For Slowing The Progression of Myopia in Children in Greater China, SEA and South Korea Markets
Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm" or "the Company"; Hong Kong stock code: 0950.HK), a research-based biopharmaceutical company, is pleased to announce that a wholly owned subsidiary of its associated company, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd (“ZKO”) has recently entered into an exclusive licensing agreement with Nevakar Inc. ("Nevakar"), a US-based privately held, late-stage, biopharmaceutical company developing multiple innovative medications in the ophthalmic and hospital injectable areasfor the development and commercialization of NVK-002 in Greater China (The People’s Republic of China (“PRC”), Hong Kong SAR, Macau SAR and Taiwan), South Korea and the Southeast Asian territories1. NVK-002 is a preservative-free, novel topical eye treatment for slowing the progression of myopia in children and is currently in a Phase 3 clinical trial study ("Childhood Atropine for Myopia Progression" or “CHAMP“ study) in the US and Europe.
Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm" or "the Company"; Hong Kong stock code: 0950.HK), a research-based biopharmaceutical company, is pleased to announce that a wholly owned subsidiary of its associated company, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd...

29/10/2010
Grand Opening of Headquarters of Powder Pharmaceuticals
[Hong Kong] Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharmaceutical” or the “Group”, Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, announced that its associated company Powder Pharmaceuticals, Incorporated (PPI) has opened a headquarters at the Hong Kong Science and Technology Park on 29 October 2010. This is PPI’s first manufacturing facility in Hong Kong, which will strengthen its foundation for the development of Zingo, a novel pharmaceutical product for pain management.

Located on the ground floor of the Wireless Centre at the Hong Kong Science and Technology Park in Shatin, the office covers an area of over 13,000 square feet with total 14 staffs. PPI is owned by Lee’s Pharmaceuticals, China Opportunity, a renowned fund in China and Sigma-tau. PPI acquire certain assets of and the global interest in Zingo and its powder intradermal injection system. Zingo, also named Lidocaine Hydrochloride Monohydrate, is a new kind of analgesic applied on intact skin to provide painkilling effect prior to venipuncture and intravenous cannulation. Zingo, which has received approval for sales from Food and Drug Administration (FDA) in the United States, is used for partial analgesia prior to veni-puncture and intravenous cannulation for both kids and adults. PPI will focus on manufacturing, developing and selling Zingo and related products.

Mr. Geoffrey F. Woodhead, Assistant Commissioner of Innovation and Technology Commission, Mr. E Anthony Tan, CEO of Hong Kong Science and Technology Park, Mr. Ugo Di Francesco, CEO of Sigma-tau, Mr. Niccolo Magnoni and Mr. Fabio De Rosa, Director of PPI, together with Board members of Lee’s Pharmaceutical, Mr. Lee Siu Fong, Chairman of Lee’s Pharmaceutical, Ms. Leelalertsuphakun Wanee, Dr. Benjamin Li and Mr. Mauro Bove, hosted the grand opening ceremony.

Dr. Benjamin Li, CEO of Lee’s Pharmaceutical said, “I am very pleased to witness the establishment of PPI’s first manufacturing base and would like to extend my gratitude to my partner for its continuous support and trust. The opening marks the success of the production and development business of Lee’s Pharmaceutical. The Board expects the business of PPI to grow in the medium to long run. This transaction represents a good investment opportunity for the Group and a more solid foundation for future growth.”
[Hong Kong] Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharmaceutical” or the “Group”, Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, announced that its associated company Powder Pharmaceuticals, Incorporated (PPI) has...

22/12/2008
Anhui Government Official Visited Zhaoke Pharmaceutical (Hefei) Co. Ltd.
2008年12月22日晚9点,安徽省委常委、合肥市委书记孙金龙率省市及高新区领导一行20余人,视察了兆科药业(合肥)有限公司,孙书记对于公司的建设和发展以及取得的成就给予了高度的评价。
在公司的会议室,孙书记等省市领导兴致勃勃地听取了公司董事长李小羿博士对公司目前经营状况、发展目标、竞争优势,以及在新产品研发等方面的介绍。
孙书记还详细询问了公司在研新药的情况及发展前景,同时非常关心公司在发展过程中碰到什么困难,需要政府哪方面的支持。李博士向孙书记汇报了公司在科技项目投入方面的工作和取得的进展,并与孙书记进行了深入的交流。孙书记对于生物制药这一高科技产业给予了高度评价,表示会加大对于公司科研项目的支持力度,希望兆科药业加快发展,争创国内国际一流企业。
视察结束后,孙书记与董事长李博士、常务副总陈跃生合影留念,勉励兆科药业把握发展机遇,开创更加美好的未来。
2008年12月22日晚9点,安徽省委常委、合肥市委书记孙金龙率省市及高新区领导一行20余人,视察了兆科药业(合肥)有限公司,孙书记对于公司的建设和发展以及取得的成就给予了高度的评价。
在公司的会议室,孙书记等省市领导兴致勃勃地听取了...

15/06/2005
Distribution Agreement to market Somatostatin
(Hong Kong, 15 June 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed an Agreement with GP-Pharm S.A., Spain for the distribution and marketing of Somonal®~Somatostatin 3mg ampoules, throughout Hong Kong and the People's Republic of China.

Somatostatin was first discovered in hypothalamic extracts and identified as a hormone that inhibited secretion of growth hormone. Subsequently, Somatostatin was found to be secreted by a broad range of tissues, including pancreas, intestinal tract and regions of the central nervous system outside the hypothalamus. Somonal® consists of Somatostatin freeze dried ampoules containing 3 mg of the active substance for dissolution purpose, is indicated for used clinically to treat carcinoid syndrome, enterocutaneous and pancreatic fistula, VIPomas, glucagonomas, severe esophageal varices bleeding.

Somatostatin is widely prescribed in China for acute variceal bleeding. Due to the high prevalence of HBV infection, China has a relatively high number of people suffered from cirrhosis and the subsequent acute esophageal varices bleeding caused by portal vein hypertension. The market for product like Somatostatin in China is quite attractive.

"We're extremely pleased to establish this distribution partnership with GP-Pharm S.A.,," stated Dr. Benjamin Li, the Chief Executive Officer of the Group. "This is the seventh product so far we have licensed-in for distribution in China from our partners in Italy and Spain. This product will allow the Group to enter into a new therapeutic area." The Group believe that successful implementation of this strategy will further expand its market shares, enrich its product pipeline and to broaden its revenue base.

About GP-Pharm

GP-Pharm P.A. is a pharmaceutical company based in Spain within the Lipotec Group whose foundation dates back from 2001. The company is undertaking the pharmaceutical and the clinical development of new products containing hormones and Cytotoxic drugs.

About Lee's

Lee's Pharmaceutical Group, as a research-driven and market-oriented biopharmaceutical group, is actively pursuing for developing proprietary products and licensing technology/product from overseas prestigious biopharmaceutical institutions and companies.

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.

For further information, please contact:
Vivian Fung
Tel: (852)2314-1282
Fax: (852)2314-1708
Email: info@leespharm.com
(Hong Kong, 15 June 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed an Agreement with GP-Pharm S.A., Spain for the distribution and marketing of Somonal®~Somatostatin 3mg ampoules, throughout...

29/03/2005
Market Isosorbide Mononitrate in HK and China
(Hong Kong, 29 March 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed a Supply and Distribution Agreement with Marvecs Services S.r.l. for the distribution and marketing of Vasdilat® slow-released capsules (Isosorbide Mononitrate), throughout Hong Kong and the People's Republic of China.

Vasdilat®~Isosorbide Mononitrate (ISMN), is a type of vasodilator with effects on both arteries and veins. The pain of coronary heart disease (angina) usually occurs when the heart requires more blood and oxygen than its blood vessels supplying the heart can deliver. Our ISMN capsule contains 30mg of isosorbide mononitrate in a slow-released formulation for oral administration, is indicated for the prevention and long-term treatment of angina pectoris associated with coronary artery disease. ISMN relaxes blood vessels, increasing the blood and oxygen supply to the heart. It reduces the pressure that the heart has to pump against and hence the Heart's work and need for oxygen, and also increases supply of oxygen to the heart by dilating the arteries which supply the heart itself. Isosorbide mononitrate is in the class of drugs called anti-anginal medications….
(Hong Kong, 29 March 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed a Supply and Distribution Agreement with Marvecs Services S.r.l. for the distribution and marketing of Vasdilat®...
16/09/2024
Lee’s Pharm participated in BIOHK2024, focusing on rare disease drug innovation
05/07/2024
The Group featured in “Top100 Chinese Chemical Pharmaceutical Companies Ranking”, with its product winning award again
12/06/2024
The Group’s in-house developed product Adapalene and Clindamycin Hydrochloride Gel was successfully launched
24/05/2024
The Group’s in-licensed products INOmax® and INOmax DSIR Plus were successfully launched
20/05/2024
Lee’s Pharmaceutical participated in the 88th PharmChina
02/04/2024
Azilsartan Tablets won the “Guangdong Prominent High-tech Products” award
08/03/2024
Zhaoke-Hefei was honored with the “Safe Enterprise” title in Hefei for the year 2023
28/02/2024
Lee’s Pharm was proudly awarded the “Caring Company Logo” for four consecutive years
16/01/2024
The Group’s in-house developed product Socazolimab Injection was successfully launched in China
27/12/2023
“STEM Experience Program for Secondary Students —— Kanya Lee Scholarship Recognition Ceremony 2023”
04/12/2023
The Group’s in-licensed product Adasuve® (Loxapine for Inhalation) obtained Drug Registration Certificate
20/11/2023
Dr. LI Xiaoyi Benjamin, Founder of Lee’s Pharm, was invited to participate in the annual “Rare Diseases Symposium 2023”
16/11/2023
Lee’s Pharmaceutical participated in the Sixth China International Import Expo
18/09/2023
Lee’s Pharm participated in BIOHK2023 and won the “Best Pharmaceutical Company of the Year Award”
16/08/2023
Zhaoke-Hefei won recognition as Innovative SME in Anhui Province
11/07/2023
Dr. LI Xiaoyi, Founder of Lee’s Pharm, was interviewed by Guangdong New Focus program
04/07/2023
Lee’s Pharm honored with “Most Popular (ESG) Enterprise Award” in 1st GBA Excellent ESG Enterprise Election
30/06/2023
Lee’s Pharm achieved a Branding Award after featuring in “Top 100 Chinese Chemical Pharmaceutical Companies Ranking”
02/06/2023
Provincial Center for ADR Monitoring visited Zhaoke-Hefei on assessment of pharmacovigilance system
23/05/2023
Lee’s Pharm successfully held The 8th Pulmonary Arterial Hypertension Summit
15/05/2023
Lee’s Pharmaceutical participated in the 86th PharmChina
02/05/2023
In-licensed product Natulan® (Procarbazine Hydrochloride Capsules) was successfully launched in China
21/04/2023
Sodium Phenylbutyrate Granules won the “Guangdong Famous High-tech Products” award
17/04/2023
Dr. LI Xiao Yi Benjamin, the Founder of Lee’s Pharm, was interviewed by Southern Metropolis Daily
13/04/2023
Nadroparin Calcium Injection won the bid in China’s new round of drug bulk-buying program
23/03/2023
Zhaoke Lian Fa, a subsidiary of Lee’s Pharm was honoured with “Excellence Enterprise Award of Gold Pilot Award 2022”
03/03/2023
Antiplatelet Thrombolysin developed by Lee’s Pharm was honoured with “Second Prize of the 8th Hefei City Industrial Achievements in Technology and Innovation”
17/02/2023
Lee’s Pharm was proudly awarded the “Caring Company Logo” for three consecutive years
19/01/2023
Inclusion of Treprostinil Injection, Teglutik® and Trittico® in the National Reimbursement Drug List
01/01/2023
“STEM Experience Program for Secondary Students —— Kanya Lee Scholarship Recognition Ceremony 2022”
21/12/2022
“Biotech Kaleidoscope”—— BIOHK 2022 International Convention sponsored by Lee’s Pharm
09/12/2022
Dr. LI Xiao Yi Benjamin, the Founder of Lee’s Pharm was interviewed by Mediazone Group during “Most Valuable Companies in Hong Kong 2022 Awards” Ceremony
16/11/2022
Media Interview by Southern Finance Omnimedia Group —— Nansha Plan: Driving R&D and Creating new opportunities for pharmaceutical industry
16/11/2022
Lee’s Pharm participated in “Caring for Rare Disease Community and Achieving Social Harmony” proposal
10/11/2022
Lee’s Pharm was honoured with “Most Valuable Companies in Hong Kong 2022 Awards” by Mediazone Group
09/11/2022
Approval of a drug product AU409 manufactured by Zhaoke Guangzhou to conduct clinical trial in the United States
24/10/2022
Lee’s Pharm has collaborated with Lok Sin Tong Community Pharmacy to donate a total of 900 boxes of masks
17/10/2022
Zhaoke-Hefei was recognized as “2022 Excellent Enterprise of National Intellectual Property” by the China National Intellectual Property Administration
30/09/2022
Azilsartan tablets obtained Drug Marketing Authorization
09/09/2022
Lee’s Pharm sponsored “The Healthcare and Biotech Road Map in Greater Bay Area” Symposium
22/08/2022
New “Excellent” Treatment for Depression ― Lee’s Pharm successfully held Satellite Meeting for Trittico®
25/07/2022
Lee’s Pharm was proudly awarded again the “Caring Company Logo”
18/07/2022
Unicycive announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and certain other Asian markets
16/07/2022
Lee’s flagship product Ferplex® was elected as “2022 Most Valuable Product in Partnership for Drug Store Chain in China”
16/07/2022
Lee’s Pharm was honoured with “2021 Top 100 Chinese Chemical Pharmaceutical Companies” Award
30/06/2022
License Transfer from Solasia to Lee’s Pharm for the Sales Promotion of Sancuso® and episil® in three cities in China
21/06/2022
New product Teglutik® obtained Drug Registration Certificate
20/05/2022
New product Natulan® obtained Drug Registration Certificate
22/04/2022
New product “Nitric Oxide for Inhalation” (INOmax®) was approved for commercialization in China
12/04/2022
Signing of the Comprehensive Strategic Cooperation Agreement between Lee’s Pharm and Rongtai Pharmaceutical
05/04/2022
Launching of Lee’s Pharm Flagship Store on Ali’s and Jingdong’s e-commerce platforms in China
13/01/2022
Zhaoke-Hefei was honoured with the award of “2021 Anhui Provincial Role Model Enterprise in Consumer Products Industry”
01/01/2022
Listing on Guidance for Family Choice Pharmacy of Lee’s Pharm signature products — Ferplex® and Yallaferon®
01/01/2022
“STEM Experience Program for Secondary Students — Kanya Lee Scholarship Recognition Ceremony”
29/12/2021
Lee’s Pharm in-house product Yallaferon® was honoured with “2021 Biopharmaceutical Excellent Brand” Award
23/12/2021
Dr. Li Xiaoyi, the founder of Lee’s Pharm was recognized as “High-Level Talent in Guangzhou Nansha New Zone (Free Trade Zone)”
23/12/2021
Lee’s Pharm Mask Donation Campaign, Sending warmth and care to the community
17/09/2021
Zhaoke Oncology was honoured with “2020 Guangzhou High-end, Precision and Sophisticated Firms” Award
03/09/2021
Zhaoke-Hefei was honoured with the award of “Anhui Provincial High-End Brand Cultivation Demonstration Enterprise in Manufacturing Industry”
24/08/2021
Baptist’s Charity Campaign for World Vision International with sponsorship from Lee’s Pharm
23/08/2021
Patented Technology “Purification of Snake Venom from Viperidae” developed by Zhaoke-Hefei was honoured with “The 8th Anhui Provincial Patent Excellence Award”
26/07/2021
Lees Pharm was honoured with 2020 Top 100 ranking of Chinese Chemical Pharmaceutical Companies
24/06/2021
The New Product “Sodium Phenylbutyrate” from Lee’s Pharm — Bringing hope to rare disease patients — Lee’s Pharm participated in the Multidisciplinary Expert Seminar on Urea Cycle Disorders
07/06/2021
Lee’s Pharm attended the Rare Diseases Conference of Guangdong Medical Association
04/06/2021
Lee’s Pharm Sponsored Symposium at the Sexual Medicine Course for Providers of Women’s Health Care
21/10/2020
HKSTP InnoAcademy — Technology Leaders of Tomorrow programme
20/10/2020
Dr Benjamin Li, CEO of Lee’s Pharmaceutical Holdings Limited was interviewed by TVB on 15 October 2020 sharing our unique concept of mask production by Powder Pharmaceuticals Incorporated (Interview Video)
20/10/2020
Zhaoke Ophthalmology and Nevakar Entered Into A License Agreement for NVK-002 — Introducing The Eye Treatment For Slowing The Progression of Myopia in Children in Greater China, SEA and South Korea Markets
11/10/2020
Concludes Series B Fundraising of approximately US$145 million for Zhaoke Ophthalmology — Marks Big Step Towards Achieving Possible Spin-off and Separate Listing
10/03/2020
HKBIO and Lee’s Pharm Mask Donation Campaign
03/03/2020
Donation of ERT-PCR Technology for New Coronavirus Detection Press Conference
30/10/2019
Lee’s Pharm Cardiovascular Products Meeting of the 30th GW-ICC
29/10/2019
Greater Pediatrics, Greater Kids, Greater China ——Ferplex of Lee’s Pharmaceutical Holdings Ltd. appeared in the 24th Congress of Chinese Pediatric Society
21/10/2019
Pre-IND meeting to communicate the combination of recombinant fully human anti- PD-L1 monoclonal antibody injection (ZKAB001 for short) and vaccinia GM-CSF/TK inactivated virus (Pexa-Vec, oncolytic virus)
14/10/2019
Building a Bridge; China-Italy Cooperation in Medical Education
24/09/2019
Wen Guohui, Deputy Secretary of the CPC Guangzhou Municipal Committee and Mayor of Guangzhou visited Zhaoke Pharmaceutical (Guangzhou) Ltd.
09/09/2019
Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd.had a very successful meeting with the reviewers from the Center for Drug Evaluation of NMPA of China
01/09/2019
East Meets West – Lee’s Pharm 9th Perinatal Medical Forum in Beijing
20/08/2019
INOMAX pre-NDA meeting
02/04/2019
RegeneRx and Lee’s Pharm to Accelerate RGN-259 Development in China
20/12/2018
Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia
06/09/2018
SillaJen and Lee’s Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in ChinaPhase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
14/02/2018
GC Pharma and Lee’s Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant
08/02/2018
CHINA ONCOLOGY FOCUS LIMITED RECEIVES APPROVAL BY CHINESE AUTHORITIES TO BEGIN CLINICAL TRIALS IN THREE SEPARATE CANCER INDICATIONS USING SORRENTO’S ANTI-PD-L1 MONOCLONAL ANTIBODY
22/11/2017
Eleison Pharmaceuticals to Partner with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, to Develop and Commercialize Glufosfamide for the China Market
21/11/2017
Shenogen Pharma and Lee’s Pharm entered into a Collaboration Agreement for a Combination Product for Treatment of Late Stage Cancers
02/11/2017
Windtree and Lee’s Pharm Close $10 Million Share Purchase Agreement Giving Lee’s Pharm Controlling Interest in Windtree
04/10/2017
Appointment Of Ms. Zhang Zhen Hua, Ada As Group Director Of Human Resources And Development Of Lee’s Pharmaceutical Holdings Limited
21/08/2017
Zingo® for Needle-free Local Analgesia is approved by Hong Kong Department of Health
26/07/2017
SillaJen and Lee’s Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
29/06/2017
Adapalene and Clindamycin combination hydrochloride Gel meetspre-specified endpoints in Phase Ib-IIa clinical study inAcne Vulgaris (Moderate to severe acne)
13/06/2017
Windtree Therapeutics and Lee’s Pharmaceutical (HK) Limited Enter Into Exclusive License and Collaboration Agreement for Development and Commercialization of KL4 Surfactant Technology Platform in Asia
09/03/2017
China FDA has Approved Zingo® for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial
27/02/2017
05/01/2017
Dilaforinitiates phase IIb clinical trial with tafoxiparin in women with slow progress of labor
05/01/2017
TOT BIOPHARM and LEE’S PHARM Signed an Exclusive Licensing Agreement on Monoclonal Antibody Drug TAB014
03/01/2017
First patient enrolled in Registration Study of Natulan® for patients with advanced Hodgkin’s lymphoma in China
02/12/2016
CVieTherapeutics Enrolled the First Patient in Phase 2b Clinical Study of Istaroxime in China
14/11/2016
Submitted New Drug Application to China FDA and Hong Kong DHon Zingo® for Needle-free Local Analgesia
07/10/2016
Kato Pharmaceuticals, Inc. and Lee’s Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize Resolvine ER in Greater China and South East Asia
27/09/2016
Dilafor raises SEK 51 million to facilitatePhase IIb clinical study with Tafoxiparin
09/09/2016
Completed The First Subject in Clinical Study forContinuous Glucose Monitoring System in Hong Kong
25/08/2016
Beijing Shenogen Pharma Group Limited and Lee’s Pharmaceutical (HK) Limited Announce Development and Commercialization Collaboration Agreement for Pexa-Vec and Icaritin in China
04/07/2016
China FDA Grants Pharmaceutical Manufacturing License to Nansha Manufacturing Facility
16/06/2016
Lee’s Pharm Announces its Chief Executive Officer, Dr. Benjamin Xiao-Yi Li awarded Honorary Fellowship from The Hong Kong University of Science and Technology
02/06/2016
RegeneRx and Lee’s Pharm Announce Acceleration ofRGN-259 Development in China
16/05/2016
APPOINTMENT OF DR. LIT-FUI LAU AS PRESIDENT AND CHIEF OPERATING OFFICER OF CVIE THERAPEUTICS LIMITED
14/04/2016
14/04/2016
14/04/2016
14/04/2016
14/04/2016
14/04/2016
14/04/2016
24/03/2016
24/03/2016
24/03/2016
24/03/2016
U.S. FDA Grants Orphan Drug Designation to Anfibatide for Treatment of Thrombotic Thrombocytopenic Purpura
14/03/2016
Successful FDA Inspection with No 483 Issued to Powder Pharmaceuticals
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
04/01/2016
Salvat and Lee’s Pharmaceutical (HK) Limited AnnounceExclusive License and Supply Agreement for Duoxal® in Greater China
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
22/12/2015
CVie Therapeutics enrolled the 1st patient for Phase 2b Clinical Trial of Rostafuroxin in Taiwan
08/12/2015
Lee’s Pharm was honored at 2015’s Forbes Asia “Best Under A Billion” Award Ceremony
08/12/2015
Lee’s Pharm Announces its Chief Executive Officer, Dr. Benjamin Li wins the EY Entrepreneur Of The Year® 2015 China Award
25/11/2015
Solasia and Lee’s Pharma Announce License, Promotion and Supply Agreement (the “Agreement”) for Sancuso®
17/11/2015
Tragara and Lee’s Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize TG02 in Greater China Market and South East Asia
28/10/2015
First Patient enrolled in Phase IIb Clinical Trial of Anfibatide in China
22/09/2015
Armetheon and Lee’s Pharma Enter into Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand
11/09/2015
Recently Published Study Shows Positive Results for ZiNGO® in Pediatric Patients
26/08/2015
WuXi PharmaTech to Be Exclusive Supplier ofLaboratory Testing Services to Lee’s Pharm
24/08/2015
BioQuiddity and Lee’s Pharmaceutical Enter Agreement to Jointly Commercialize – Two Infusion Pharmaceuticals in China, Taiwan, Hong Kong, and Macau
03/08/2015
CVIE Therapeutics obtained approval from the Ministry of Health and Welfare for conducting Phase 2b Clinical Trial of Rostafuroxin in Taiwan
03/07/2015
Presentation at The First Chinese Symposium of Thrombosis and Haemostasis inAssociation with the ISTH Congress
30/03/2015
First patient enrolled in Phase Ib-IIa clinical studyofAdapalene and Clindamycin combination hydrochloride Gel forAcne Vulgaris (Moderate to severe acne)
09/03/2015
Lee’s Pharm Joins Hang Seng Broad Consumption Index, Hang Seng Mainland Consumer Goods Index, Hang Seng Global Composite Index and Hang Seng Composite Index
26/02/2015
Lee’s Zhaoke Pharmaceutical Ranks Second in 2014 for Number of Declared New Drug Application
27/11/2014
EyeSense Attracts Lee’s Pharmaceutical Holdings as Strategic Investor
19/11/2014
Ikaria and Lee’s Pharmaceutical Announce Strategic Partnership for the Registration and Commercialization of Ikaria’s INOMAX ® Total Care Package in the PRC, HK, Macau and Taiwan
12/11/2014
Patients Enrollment Completed in Phase II Clinical Study of Anfibatide in China
12/11/2014
Lee’s Pharmaceutical successfully obtained the Imported Drug License for MICTONORM® in China
10/11/2014
Lee’s Pharm Becomes a Constituent Stock of MSCI China Index under MSCI Global Small Cap Indexes
06/10/2014
SORRENTO AND LEE’S PHARMACEUTICAL ENTER INTO EXCLUSIVE CHINA LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE ANTI-PD-L1 ANTIBODY
01/10/2014
01/10/2014
01/10/2014
01/10/2014
08/09/2014
License, Distribution and Supply Agreement to market Cholecalciferol in China, Hong Kong, Macau and Taiwan
01/09/2014
01/09/2014
01/09/2014
01/09/2014
01/09/2014
01/09/2014
01/08/2014
01/08/2014
01/08/2014
01/08/2014
01/07/2014
01/07/2014
01/07/2014
23/06/2014
Chinese FDA Accepts Phase 2 IND for RGN-259 for Dry Eye
01/06/2014
01/06/2014
09/05/2014
ScinoPharm and Lees Pharmaceutical Jointly Develop a Number of Drug Products for theChinese Market
01/05/2014
01/05/2014
01/05/2014
01/05/2014
01/05/2014
01/05/2014
01/05/2014
01/05/2014
16/04/2014
License, Distribution and Supply Agreement to market Neridronic Acid in China, Hong Kong, Macau and Taiwan
01/04/2014
01/04/2014
03/03/2014
Powder Pharmaceuticals Hong Kong made the first shipment to US
01/03/2014
27/02/2014
ZHAOKE New Facility in Hefei Received GMP Approval by CFDA
20/02/2014
Dilafor enters into a license and partnership agreement with Lee’s Pharmaceutical
01/01/2014
01/01/2014
01/01/2014
01/01/2014
01/01/2014
25/11/2013
Execution of License, Distribution & Supply Agreement for Zingo®(lidocaine hydrochloride monohydrate) between Powder and Marathon
01/11/2013
01/11/2013
01/11/2013
01/11/2013
01/11/2013
01/11/2013
01/11/2013
01/11/2013
01/11/2013
03/10/2013
First Patient Enrolled in Phase II Clinical Study of Istaroxime in Italy
02/10/2013
Lee’s Pharm announces that China registration study of Trazodone Hydrochloride Tablets for depression has met its primary endpoint
04/09/2013
Jennerex and Lee’s Pharm announces that its phase 2 study of Pexa-Vec in second-line advanced liver cancer did not meet its primary endpoint
28/08/2013
Clinical Trial Application to Conduct Phase III APEX Study of Betrixaban in China was Accepted for Review by China FDA
06/08/2013
Clinical Trial Application for Phase III study for Gimatecan was accepted for review by China FDA
01/08/2013
Powder Pharmaceuticals Hong Kong as theManufacturing Site for ZingoTM is Approved by FDA
24/07/2013
Lee’s Present Positive Anfibatide Phase I and II Clinical Data showing “a new way to anti-platelet” at ISTH in Amsterdam
15/07/2013
Obtained Imported Drug License for Levocarnitine Oral Solution in China
10/07/2013
First Patient Enrolled in Phase III Clinical Trial of Prulifloxacin in China
09/07/2013
Powder Pharmaceuticals Hong Kong Manufacturing Facility is Acceptable by US FDA
01/07/2013
01/07/2013
01/07/2013
01/07/2013
01/07/2013
01/07/2013
01/07/2013
27/06/2013
Patients Enrollment Completed in Clinical Study on Trazodone Hydrochloride Tablets for Depression
13/06/2013
First Patient Enrolled in Phase IIb Clinical Trial of Rostafuroxin in Italy
03/06/2013
Submitted Clinical Study Application to the CFDA for Istaroxime in treatment of Acute Decompensated Heart Failure in China
22/05/2013
Jennerex and Lee’s Pharmaceutical Announce Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
16/04/2013
Lee’s Pharmaceuticals Announces it has Obtained the Imported Drug License in China for Remodulin (Treprostinil) injection
09/04/2013
Powder Pharmaceuticals Appointed Two Members to Join the Board of Directors
01/04/2013
26/02/2013
Jennerex and Lee’s Pharmaceutical Announce Expansion of Partnership for Additional Pexa-Vec Indications in China
13/02/2013
Jennerex Announces Nature Medicine Publication Highlighting Randomized Overall Survival Benefit of Lead Product Candidate, Pexa-Vec (JX-594) in Patients with Advanced Hepatocellular Carcinoma (HCC)
13/02/2013
Jennerex Announces Cancer Research Publication Demonstrating Vascular Targeting Mechanism of Action of Lead Product Candidate, Pexa-Vec (JX-594)
08/02/2013
Dyax Corp. and CVie Therapeutics Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in China, Hong Kong and Macau
29/01/2013
Portola and Lee’s Pharmaceutical Enter into Agreement to Expand Phase 3 APEX Study of Betrixaban into China
14/12/2012
License and Supply Agreement signed to market Leuprolide in China, Hong Kong and Macau
01/12/2012
01/12/2012
01/12/2012
01/12/2012
01/12/2012
01/12/2012
01/12/2012
22/11/2012
Lee’s Pharmaceutical Announces First Patient Treated in Phase 2b Clinical Trial of JX-594 at Queen Mary Hospital
02/11/2012
Powder Pharmaceuticals made submission to US FDA for approval of Hong Kong manufacturing facility
29/10/2012
A newspaper article reported at The Standard,“There is no cure for all our ills, but there are people who are devoted to the pursuit of making life a little bearable”
25/10/2012
Lee’s Pharmaceutical Appoints Dr. Giuseppe Bianchi to as Chief Scientific Officer
08/10/2012
Lee’s Pharmaceutical Appoint Dr. Lit-Fui Lau to its Senior Management Team
01/09/2012
01/09/2012
01/09/2012
01/09/2012
01/09/2012
01/09/2012
01/09/2012
01/09/2012
31/08/2012
Lee’s Pharm wins the Technological Achievement Award in the 2012 Hong Kong Awards for Industries
28/08/2012
08/08/2012
Issuance of shares by CVie Therapeutics and Phase IIb Clinical Study Application for Rostafuroxin in China
06/08/2012
First patient enrolled in Phase Ib-IIa clinical study of Anfibatide for acute coronary syndrome (ACS)
17/07/2012
RegeneRx and Lee’s Pharmaceutical Complete License Agreement for Development of RegeneRx Product Candidates in China (including Hong Kong and Macau) and Taiwan
11/07/2012
Phase III clinical study of L-Carnitine on chronic Heart Failure patients with acute episode meets the primary endpoint
01/06/2012
01/06/2012
01/06/2012
01/06/2012
10/04/2012
Lee’s Pharmaceutical licenses GI safer aspirin product for China from PLx Pharma
21/03/2012
Jennerex and Lee’s Pharmaceutical Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecanin Patients with Metastatic Colorectal Cancer
14/03/2012
Obtained Medical Device Registration Certificate of Hyalofemme® from the SFDA
01/03/2012
01/03/2012
06/02/2012
MAJOR MILESTONE ACHIEVEMENT IN AN ASSOCIATED COMPANY
01/12/2011
01/12/2011
30/11/2011
Jennerex and Lee’s Pharmaceutical Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer
22/11/2011
Lee’s Pharm was honored at 2011’s Forbes Asia “Best Under A Billion” Award Ceremony
07/11/2011
Jennerex and Lee’s Pharmaceutical Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
12/09/2011
Submitted New Drug Application to the SFDA on RemodulinFor Treatment of Pulmonary Arterial Hypertension
09/09/2011
Jennerex and Lee’s Pharmaceutical Announce Publication of Interim Clinical Data of JX-594 Followed by Sorafenib Demonstrating Tumor Responses in Liver Cancer
01/09/2011
Jennerex and Lee’s Pharmaceutical Announce the Publicatiion of Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic PoxvirusJX 594 to Tumors
01/09/2011
01/09/2011
01/09/2011
01/09/2011
01/09/2011
01/09/2011
03/08/2011
Jennerex and Lee’s Pharmaceutical Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
01/08/2011
01/08/2011
01/08/2011
20/07/2011
Completed Last Patient Follow-up in Clinical Study on Acetyl L-Carnitine Tablets for treatment of Peripheral Neuropathy
30/05/2011
30/05/2011
23/05/2011
Jennerex and Lee’s Pharmaceutical Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
15/05/2011
15/05/2011
12/05/2011
Patients Enrollment completed in Clinical Study on Acetyl L-Carnitine Tablets for treatment of Peripheral Neuropathy
09/05/2011
Lee’s Pharma Announced the New Drug Registration of Natulan® for Hodgkin’s Disease in China
18/04/2011
Lee’s Pharm Announced the Completion of Phase I Study for its first-in-class drug Declotana®
13/04/2011
Patients Enrollment completed in Clinical Study on Propiverine Hydrochloride Modified Release Capsules for treatment of Urinary Incontinence
10/04/2011
20/03/2011
04/03/2011
Powder Pharmaceuticals Incorporated Enters into Agreement with Health-Chem Diagnostics, LLC obtaining Exclusive Manufacturing and Marketing Rights for TD Glucose in PRC, Hong Kong and other Asian Countries
14/02/2011
Propionyl-L-Carnitine Clinical Study Meets Primary and Secondary Endpoint of Treating Peripheral Arterial Diseases
05/01/2011
Approval received to initiate clinical study for Trittico®
31/12/2010
30/12/2010
Lee’s Pharmaceutical Enters into Agreement with CID S.r.l. obtaining Exclusive Distribution of PTCA Balloon Catheters, Chrono Carbostent and Optima DES Carbostent in China
06/12/2010
Lee’s Pharm Accredited “Hong Kong Outstanding Enterprises 2010”
29/10/2010
Grand Opening of Headquarters of Powder Pharmaceuticals
22/09/2010
Grand Opening of Powder Pharmaceuticals Incorporated
09/08/2010
09/08/2010
02/07/2010
UNITED THERAPEUTICS AND LEE’S PHARMACEUTICAL SIGN REMODULIN DISTRIBUTION AGREEMENT FOR CHINA
02/07/2010
Patients Enrollment completed in Clinical Study on Propionyl-L-Carnitine Tablets for treatment of Peripheral Arterial Diseases
09/06/2010
Lee’s Pharm Accredited “Asia’s Best Companies 2010 – (China) Best Small Cap” Ranked 2nd
07/06/2010
Best Small-cap Company
17/05/2010
Warm congratulations to the successful listing of Lee’s Pharm on the Main Board
17/05/2010
Lee’s Pharmaceutical Trading Debut
24/04/2010
15/03/2010
RECORDATI AND LEESPHARM ANNOUNCE PARTNERSHIP FOR ZANIDIP® IN CHINA
29/01/2010
Obtained Registration Certificate for Medical Device of Veloderm® in China
15/01/2010
Obtained Renewal of Imported Drug License for Co-dergocrine Mesylate in China
14/01/2010
Obtained Renewal of Imported Drug License for Ferplex® Iron Proteinsuccinylate Oral Solution in China
31/12/2009
Distribution Agreement signed to market Lercanidipine tablets in Hong Kong and Macau
28/12/2009
23/11/2009
JENNEREX AND LEE’S PHARMACEUTICALS ANNOUNCE PARTNERSHIP FOR JX-594 IN CHINA
06/11/2009
Phase I Clinical Study on Antiplatelet Thrombolysin injection
15/10/2009
05/07/2009
28/06/2009
14/06/2009
31/05/2009
29/04/2009
20/03/2009
14/03/2009
08/03/2009
02/03/2009
Lee’s Pharmaceutical Enters into Agreement with Nippon ShinyakuA Move To Accelerate Market Diversification in China
28/02/2009
17/02/2009
17/02/2009
22/12/2008
Anhui Government Official Visited Zhaoke Pharmaceutical (Hefei) Co. Ltd.
17/12/2008
Lee’s Pharmaceutical Establishes New R&D Centre at the Hong Kong Science ParkTo Bolster the Group’s R&D Capabilities
13/12/2008
13/12/2008
12/12/2008
01/12/2008
01/12/2008
01/12/2008
29/11/2008
29/09/2008
28/08/2008
16/08/2008
18/07/2008
12/07/2008
22/06/2008
20/06/2008
14/06/2008
13/06/2008
06/06/2008
30/05/2008
28/05/2008
28/05/2008
28/05/2008
28/05/2008
23/05/2008
13/05/2008
New Drug Approval for Eyprotor® (Protein-free Calf Blood Extract Eye-gel) in China
09/05/2008
09/05/2008
19/12/2007
LEE’S SIGNED COLLABORATION AGREEMENT WITH NOVELOS
20/09/2007
SIGMA-TAU STRENGTHENS ITS PARTICIPATION IN LEE’S PHARMACEUTICALS
09/08/2007
Exclusive Distribution Agreement Signed for Aloxi® injection in China
25/06/2007
Completed the Pharmacokinetic Study of HIBOR® (Bemiparin Sodium)
18/06/2007
Distribution Agreement Signed with Italfarmaco of Italy for Serestill® in China
15/06/2007
Important milestones achieved in Clinical Studies of Stent & Balloon Catheter
18/10/2006
New Indication Approved for Cervicitis for Yallaferon
22/09/2006
Marketing Approval for Slounase® (Hemocoagulase) in China
23/06/2006
Approval to initiate a Clinical Trial for Hibor
20/02/2006
Approval for Clinical Study on Antiplatelet Thrombolysin injection
20/02/2006
Distribution agreement signed to market Propiverine Hydrochloride
20/12/2005
New Product Launch in Hong Kong – HIBOR® (Bemiparin Sodium)
20/12/2005
Completion of the Study of Yallaferon® in Cervicitis Patients
17/10/2005
New Drug Approval for Hemocoagulase snake venom
28/09/2005
Distribution of HORUS®S Coronary Stent
07/09/2005
New Indication Approved for Yallaferon®
15/06/2005
Distribution Agreement to market Somatostatin
08/06/2005
Complete patients recruitment for Cervicitis
09/05/2005
Completion of the Clinical Study of Eye-gel
29/03/2005
Market Isosorbide Mononitrate in HK and China
16/03/2005
Progress in Clinical Study of Eye-gel
04/02/2005
Good progress in Clinical Study in Cervicitis
01/01/1970
01/01/1970
01/01/1970
01/01/1970
01/01/1970